Literature DB >> 31605220

Male sex and anterior wall tumor location as risk factors for urinary dysfunction after laparoscopic rectal surgery.

Hiroki Hamamoto1, Masashi Yamamoto2, Shinsuke Masubuchi2, Masatsugu Ishii2, Wataru Osumi2, Keitaro Tanaka2, Junji Okuda2, Kazuhisa Uchiyama2.   

Abstract

BACKGROUND: Total mesorectal excision (TME) has decreased the local recurrence rate and improved the overall survival of rectal cancer patients. However, urinary dysfunction remains a clinical problem after rectal cancer surgery. The aim was to assess the risk factors for postoperative urinary dysfunction.
METHODS: This study was a single-center, retrospective analysis of 104 patients who underwent laparoscopic rectal surgery between November 2016 and October 2017. Postoperative urinary dysfunction was defined as the need for urinary catheter re-insertion or the presence of residual urine (≥ 150 mL) postoperatively.
RESULTS: Postoperative urinary dysfunction was seen in 18 patients (17%). Multivariate analysis showed that male sex (odds ratio 3.89, p = 0.034) and anterior wall tumor location (odds ratio = 4.07, p = 0.037) were the predictors of postoperative urinary dysfunction. Compared with patients without risk factors, those with the two risk factors needed longer hospital stays (16 days vs. 30 days, p = 0.0022).
CONCLUSION: Male sex and anterior wall tumor location were the risk factors for urinary dysfunction after laparoscopic rectal surgery.

Entities:  

Keywords:  Laparoscopic rectal surgery; Neurovascular bundle; Pelvic plexus; Postoperative urinary dysfunction

Mesh:

Year:  2019        PMID: 31605220     DOI: 10.1007/s00464-019-07186-y

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  1 in total

1.  Validation of a scoring system to predict bladder dysfunction after laparoscopic rectal cancer surgery.

Authors:  Kwan Ho Lee; Chungki Min; Hyung Ook Kim; Yong Bog Kim; Yongjun Park; Jung Tak Son; Sung Ryol Lee; Kyung Uk Jung; Hungdai Kim
Journal:  Langenbecks Arch Surg       Date:  2022-06-24       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.